This study was designed to assess the efficacy and safety of Infliximab (IFX) in the treatment of ocular manifestations in patients with Bechet’s disease, namely BD-associated refractory posterior uveitis (PU) as expressed by VA improvement from baseline and to investigate the efficacy of IFX to reduce disease flare-up, to assess the proportion of relapse free subjects at the end of follow-up, and the percentage of patients achieving a complete or partial remission, and to evaluate the tolerability and safety of the treatment. Twenty patients with refractory Bechet uveitis PU (17 males and 3 females) were included in this study. patients were subjected to full history taking, physical examination, purified protein derivative (PPD) test, laboratory tests including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), blood cell count with differential count, renal and liver function, antinuclear antibody titer .Ophthalmologic evaluation consisted of a complete ocular examination including best-corrected VA , slit-lamp biomicroscopy, tonometry and ophthalmoscopy, optical coherence tomography (OCT) and fundus fluorescein angiography (FFA). By the end of week 8 ( induction), we observed a highly significant improvement in VA (right eyes: 0.10.09 vs 0.60.2, P0.001) (Left eyes: 0.10.17 vs 0.60.3, P0.001), and by the end of week 32 there was further improvement in VA, (right eye: 0.60.2 vs 0.80.2, P0.001), (left eyes: 0.60.3 vs 0.80.2, P0.001), but this improvement was nearly the same by the end of week 58, (right eyes: 0.80.2 vs 0.80.2) (left eyes: 0.80.2 vs 0.80.2). It was noted that improvement in VA was more evident in group A than in group B (P<0.05). At the end of a follow-up of 12 months, 16/20 (80%) patients showed a complete remission, 4/20(20%) showed partial response, none of the patients were non-responders. All of the patients (20) who were taking corticosteroids were able to stop it by week 22 during infliximab treatment, and all showed a reduction in extraocular manifestations of Bechet’s disease. None of the patients had worsening VA or new onset ocular complications. Infliximab seems to be a useful alternative therapy for patients with sight-threatening uveitis unresponsive to the standard immunosuppressive therapy. Although infliximab can be used as first-line medications in bilateral OBD, unilateral case with visual acuity below (6/60) may also need initial infliximab infusion as the first-line drug. Azathioprine can be used as a long-term therapy to control recurrent attacks upon first suppression of ocular inflammation by biologicals. Infliximab is also effective treatment in ocular Bechet’s disease regarding long term therapy.